Synadiet welcomes the European Commissions presentation of the Biotech Act I and the ongoing work towards the Biotech Act II. Strengthening Europes biotechnology sector is essential to maintaining global competitiveness and securing Europes strategic autonomy in innovation. Achieving this objective requires a regulatory framework that actively supports innovation.
SYN
Synadiet
Industry association · France · EU Transparency Register 037623530780-36
3
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 410 trade unions and professional associations on this site, they rank #198 by legislative files engaged, a count of participation, not a measure of influence.
0.4
declared lobbying FTE
self-declared
€50K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2018
in the register since
Declares membership of
- European Federation of Associations of Health Product Manufacturers (EHPM)
- Mouvement des Entreprises de France (MEDEF)
- La liste complète des structures partenaires de Synadiet est disponible sur notre site internet : https://www.synadie…
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Trade unions and professional associations
- Registered as
- Syndicat national des compléments alimentaires (Synadiet)
- Head office
- Paris, France
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Synadiet in PolicySpeak: request access →
Work at Synadiet? so we know who speaks for it.
Their record over time
Synadiet filed 3 positions between 22 Apr 2020 and 10 Jun 2026, across 3 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2020 · 1 filed2026 · 2 filed
What they argued
Synadiet welcomes the European Commissions presentation of the Biotech Act I and the ongoing work towards the Biotech Act II. Strengthening Europes biotechnology sector is essential to maintaining global competitiveness and securing Europes strategic autonomy in innovation. Achieving this objective requires a regulatory framework that actively supports innovation.
We deliver the Commission for the opportunity to give our feedback on the Draft amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council regarding Botanical species containing hydroxy anthracene derivatives. Our comments are detailed below.
Filed in French · English published by the European Commission
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Synadiet next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 85.
Is this your organization?
Everything on this page comes from Synadiet’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.